This strategic move aims to address the increasing global demand for biologics, enhancing ProBioGen's ability to support partners from cell line development t
The AGE1.CR.pIX cell line's versatility allows it to support a wide range of viruses and vaccine types
Nous-209 has been developed using the Nouscom's viral vector platform
ProBioGen previously developed the cell line and the manufacturing process and provided the initial clinical material for ImmunOs' innovative biologic.
ProBioGen was able to carry on its rapid growth trajectory by completing a significantly increased number of projects.
Julian Collins, Jana Windt and Michiel Stork join biopharma company’s leadership team
The AGE1.CR.pIX cell line is derived from primary cells of a duck embryo and was designed to comply with health authority guidelines
The new project further expands the partner's long-term collaboration on new technologies for R&D
It allows users to generate cell lines suitable for clinical development without their own starter cells, vectors or prior experience in the field.
They also noted ProBioGen's digitalization investments and strategy, as well as its support for its employees.
Subscribe To Our Newsletter & Stay Updated
